share_log

百利天恒(688506.SH):注射用BL-M17D1(ADC)项目治疗晚期实体瘤获得I期临床试验批准通知书

Baili Tianheng (688506.SH): The injection of BL-M17D1 (ADC) project for the treatment of advanced solid tumors has been approved for Phase I clinical trials.

Gelonghui Finance ·  Jun 21 07:45

On June 21st, Gelonhui reported that Bailitianheng (688506.SH) announced to have received the official approval notice of"Drug Clinical Trial Approval" issued by the National Medical Products Administration (NMPA). The company's independent research and development of innovative biomedicine BL-M17D1 (ADC) clinical trial received approval. BL-M17D1 is an ADC drug derived from the same new small molecule technology platform as BL-B16D1, and shares the same new "linker + toxin" platform as BL-B16D1. It is indicated for advanced solid tumors.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment